EMA Authorised: Vijoice (alpelisib) — Novartis Europharm Limited

View source ↗

Summary

EMA authorised Vijoice (alpelisib) by Novartis Europharm Limited with conditional approval for genetic diseases of growth disorders; orphan medicine designation…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Genetic Diseases Inborn
• Growth Disorders

Drugs mentioned

• VIJOICE (ALPELISIB)

Snippet

Status: Authorised. Therapeutic area: Genetic Diseases, Inborn;Growth Disorders. MAH: Novartis Europharm Limited. Decision date: 15/07/2026. Conditional approval. Orphan medicine